ATP3 Men

The ATP III Men score estimates a man’s 10‑year risk of coronary heart disease based on age, cholesterol, blood pressure, smoking, and diabetes.

Age
20-34-935-39-440-44045-49+350-54+655-59+860-64+1065-69+1170-74+1275-79+13
Tot Chol
<160 (4.9) & Age 20-790160-199 (5.9-5.3)& Age 70-790200-239 (5.3-6.2)& Age 70-790160-199 (4.9-5.3)& Age 60-69+1200-239 (5.3-6.2)& Age 60-69+1240-279 (6.2-7.3)& Age 70-79+1280+ (7.3+)& Age 70-79+1160-199 (4.9-5.3)& Age 50-59+2240-279 (6.2-7.3)& Age 60-69+2160-199 (4.9-5.3)& Age 40-49+3200-239 (5.3-6.2)& Age 50-59+3280+ (7.3+)& Age 60-69+3160-199 (4.9-5.3)& Age 20-39+4240-279 (6.2-7.3)& Age 50-59+4200-239 (5.3-6.2)& Age 40-49+5280+ (7.3+)& Age 50-59+5240-279 (6.2-7.3)& Age 40-49+6200-239 (5.3-6.2)& Age 20-39+7280+ (7.3+)& Age 40-49+8240-279 (6.2-7.3)& Age 20-39+9280+ (7.3+)& Age 20-39+11
Smoker
Nonsmoker & Age 20-790Smoker & Age 60-79+1Smoker & Age 70-79+1Smoker & Age 50-59+3Smoker & Age 40-49+5Smoker & Age 20-39+8
HDL
60+ (1.6+)-150-59 (1.3-1.6)040-49 (1.0-1.3)+1<40 (1.0)+2
Syst BP
<1200120-129 & Untreated0120-129 & Treated+1130-139 & Untreated+1140-159 & Untreated+1130-139 & Treated+2140-159 & Treated+2160+ & Untreated+2160+ & Treated+3

Indications for Use

Used to guide LDL‑C–based treatment decisions in adult men by integrating age, cholesterol levels, blood pressure, smoking, and diabetes to estimate 10‑year CHD risk and determine thresholds for therapeutic lifestyle changes or statin initiation. Clinically useful for risk‑stratified cholesterol management, especially in men with multiple risk factors.

Insights & Cautions

Start by recognizing it estimates 10‑year CHD risk using traditional factors.

  • Underestimates risk in younger men and those with high lifetime risk but low short‑term risk.
  • Not calibrated to contemporary populations; may misclassify patients with obesity, metabolic syndrome, or subclinical atherosclerosis.
  • Does not account for CAC scoring or newer biomarkers, limiting precision.
  • Use cautiously in borderline cases and consider complementary tools when LDL‑lowering decisions hinge on accurate risk estimation.